Compare · MEDP vs OABI
MEDP vs OABI
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and OmniAb Inc. (OABI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and OABI operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $17.21B, about 26.0x OABI ($661.5M).
- Over the past year, MEDP is up 18.6% and OABI is up 170.0% - OABI leads by 151.4 points.
- MEDP has been more active in the news (13 items in the past 4 weeks vs 2 for OABI).
- MEDP has more recent analyst coverage (25 ratings vs 5 for OABI).
- Company
- Medpace Holdings Inc.
- OmniAb Inc.
- Price
- $618.31-1.68%
- $4.59-2.96%
- Market cap
- $17.21B
- $661.5M
- 1M return
- +0.58%
- +3.49%
- 1Y return
- +18.63%
- +170.00%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2021
- News (4w)
- 13
- 2
- Recent ratings
- 25
- 5
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest MEDP
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 4 filed by Medpace Holdings Inc.
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.23% to 12,303 units (SEC Form 4)
- Director Kraft Robert O. converted options into 32 shares, increasing direct ownership by 3% to 987 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.13% to 27,861 units (SEC Form 4)
- President & CEO Troendle August J. sold $30,320,929 worth of shares (48,667 units at $623.03), decreasing direct ownership by 13% to 338,225 units (SEC Form 4)
- UBS resumed coverage on Medpace with a new price target
- President & CEO Troendle August J. sold $1,589,941 worth of shares (2,564 units at $620.10), decreasing direct ownership by 0.66% to 386,892 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $27,403,895 worth of shares (43,916 units at $624.01), decreasing direct ownership by 10% to 389,456 units (SEC Form 4)
Latest OABI
- OmniAb to Report Third Quarter 2026 Financial Results on October 30
- OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
- OmniAb to Host Investor & Analyst Day on October 6, 2026
- OmniAb to Participate in Upcoming Investor Conferences
- OmniAb Raises 2026 Financial Guidance
- OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
- SEC Form 10-Q filed by OmniAb Inc.
- OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
- SEC Form 4 filed by Chief Operating Officer Nwachuku Amechi Ekeke